Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P06702

UPID:
S10A9_HUMAN

ALTERNATIVE NAMES:
Calgranulin-B; Calprotectin L1H subunit; Leukocyte L1 complex heavy chain; Migration inhibitory factor-related protein 14; S100 calcium-binding protein A9

ALTERNATIVE UPACC:
P06702; D3DV36; Q6FGA1; Q9NYM0; Q9UCJ1

BACKGROUND:
The S100 calcium-binding protein A9, known as Calprotectin L1H subunit, is integral to regulating immune responses and inflammation. It enhances neutrophil functions, such as phagocytosis and degranulation, and plays a role in leukocyte arachidonic acid metabolism. S100A9's involvement in activating NADPH-oxidase and its antimicrobial activity highlight its significance in host defense mechanisms. Additionally, it acts as an alarmin, stimulating innate immune cells through pattern recognition receptors, thereby amplifying pro-inflammatory cascades.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of S100 calcium-binding protein A9 offers promising avenues for developing novel therapeutic interventions aimed at controlling inflammation and enhancing immune defense.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.